Trade X4 Pharmaceuticals, Inc. - XFOR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
X4 Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 1.04 |
| Open* | 1.07 |
| 1-Year Change* | 22.99% |
| Day's Range* | 1.04 - 1.07 |
| 52 wk Range | 0.65-2.58 |
| Average Volume (10 days) | 1.23M |
| Average Volume (3 months) | 60.60M |
| Market Cap | 208.00M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 164.43M |
| Revenue | N/A |
| EPS | -1.05 |
| Dividend (Yield %) | N/A |
| Beta | 0.72 |
| Next Earnings Date | Nov 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 26, 2023 | 1.04 | 0.03 | 2.97% | 1.01 | 1.08 | 1.00 |
| Sep 25, 2023 | 1.02 | 0.01 | 0.99% | 1.01 | 1.05 | 0.99 |
| Sep 22, 2023 | 1.01 | -0.01 | -0.98% | 1.02 | 1.05 | 1.01 |
| Sep 21, 2023 | 1.02 | 0.02 | 2.00% | 1.00 | 1.06 | 0.98 |
| Sep 20, 2023 | 1.01 | -0.03 | -2.88% | 1.04 | 1.08 | 1.00 |
| Sep 19, 2023 | 1.06 | 0.01 | 0.95% | 1.05 | 1.07 | 1.03 |
| Sep 18, 2023 | 1.06 | -0.01 | -0.93% | 1.07 | 1.10 | 1.03 |
| Sep 15, 2023 | 1.08 | -0.08 | -6.90% | 1.16 | 1.18 | 1.06 |
| Sep 14, 2023 | 1.18 | 0.01 | 0.85% | 1.17 | 1.19 | 1.11 |
| Sep 13, 2023 | 1.18 | 0.02 | 1.72% | 1.16 | 1.21 | 1.13 |
| Sep 12, 2023 | 1.15 | -0.05 | -4.17% | 1.20 | 1.21 | 1.15 |
| Sep 11, 2023 | 1.22 | 0.02 | 1.67% | 1.20 | 1.22 | 1.16 |
| Sep 8, 2023 | 1.20 | -0.02 | -1.64% | 1.22 | 1.24 | 1.20 |
| Sep 7, 2023 | 1.24 | -0.01 | -0.80% | 1.25 | 1.26 | 1.20 |
| Sep 6, 2023 | 1.26 | -0.03 | -2.33% | 1.29 | 1.29 | 1.19 |
| Sep 5, 2023 | 1.27 | -0.03 | -2.31% | 1.30 | 1.30 | 1.23 |
| Sep 1, 2023 | 1.27 | 0.01 | 0.79% | 1.26 | 1.29 | 1.25 |
| Aug 31, 2023 | 1.26 | -0.03 | -2.33% | 1.29 | 1.31 | 1.25 |
| Aug 30, 2023 | 1.31 | 0.03 | 2.34% | 1.28 | 1.31 | 1.24 |
| Aug 29, 2023 | 1.28 | 0.00 | 0.00% | 1.28 | 1.31 | 1.26 |
X4 Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, November 1, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Q3 2023 X4 Pharmaceuticals Inc Earnings Release Q3 2023 X4 Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 3 | 0 | 3.5 |
| Total Operating Expense | 87.569 | 85.107 | 63.036 | 52.269 | 49.385 |
| Selling/General/Admin. Expenses, Total | 27.02 | 24.702 | 20.942 | 16.64 | 18.406 |
| Research & Development | 61.058 | 50.647 | 41.932 | 30.163 | 30.979 |
| Unusual Expense (Income) | -0.509 | 9.758 | 0.162 | 5.466 | 0 |
| Operating Income | -87.569 | -85.107 | -60.036 | -52.269 | -45.885 |
| Interest Income (Expense), Net Non-Operating | -2.073 | -3.998 | -2.852 | -0.767 | -0.23 |
| Other, Net | -4.197 | 0.426 | 0.905 | 0.229 | 3.094 |
| Net Income Before Taxes | -93.839 | -88.679 | -61.983 | -52.807 | -43.021 |
| Net Income After Taxes | -93.867 | -88.696 | -62.131 | -52.807 | -43.021 |
| Net Income Before Extra. Items | -93.867 | -88.696 | -62.131 | -52.807 | -43.021 |
| Net Income | -93.867 | -88.696 | -62.131 | -52.807 | -43.021 |
| Total Adjustments to Net Income | -2.546 | -13.943 | 0 | -0.592 | 0 |
| Income Available to Common Excl. Extra. Items | -96.413 | -102.639 | -62.131 | -53.399 | -43.021 |
| Income Available to Common Incl. Extra. Items | -96.413 | -102.639 | -62.131 | -53.399 | -43.021 |
| Dilution Adjustment | |||||
| Diluted Net Income | -96.413 | -102.639 | -62.131 | -53.399 | -43.021 |
| Diluted Weighted Average Shares | 63.526 | 25.749 | 20.077 | 11.53 | 2.38466 |
| Diluted EPS Excluding Extraordinary Items | -1.51769 | -3.98614 | -3.09464 | -4.63131 | -18.0408 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -1.5229 | -3.73981 | -3.08939 | -4.15724 | -16.573 |
| Revenue | 0 | 0 | 3 | 3.5 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | |||||
| Total Operating Expense | 25.805 | 29.304 | 25.577 | 20.154 | 20.57 |
| Selling/General/Admin. Expenses, Total | 10.204 | 7.241 | 6.563 | 6.044 | 6.749 |
| Research & Development | 15.601 | 22.063 | 19.014 | 14.11 | 13.821 |
| Unusual Expense (Income) | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -25.805 | -29.304 | -25.577 | -20.154 | -20.57 |
| Interest Income (Expense), Net Non-Operating | -0.234 | -0.274 | 0.244 | -1.004 | -0.579 |
| Other, Net | -29.658 | 5.562 | -3.757 | -0.441 | -0.059 |
| Net Income Before Taxes | -55.697 | -24.016 | -29.09 | -21.599 | -21.208 |
| Net Income After Taxes | -55.712 | -24.02 | -29.104 | -21.586 | -21.212 |
| Net Income Before Extra. Items | -55.712 | -24.02 | -29.104 | -21.586 | -21.212 |
| Net Income | -55.712 | -24.02 | -29.104 | -21.586 | -21.212 |
| Total Adjustments to Net Income | 0 | 0 | 0 | -0.287 | 0 |
| Income Available to Common Excl. Extra. Items | -55.712 | -24.02 | -29.104 | -21.873 | -21.212 |
| Income Available to Common Incl. Extra. Items | -55.712 | -24.02 | -29.104 | -21.873 | -21.212 |
| Diluted Net Income | -55.712 | -24.02 | -29.104 | -21.873 | -21.212 |
| Diluted Weighted Average Shares | 168.738 | 145.967 | 101.176 | 83.211 | 35.437 |
| Diluted EPS Excluding Extraordinary Items | -0.33017 | -0.16456 | -0.28766 | -0.26286 | -0.59858 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.33017 | -0.16456 | -0.28766 | -0.26286 | -0.59858 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 128.677 | 87.878 | 83.307 | 129.278 | 35.08 |
| Cash and Short Term Investments | 121.718 | 81.787 | 78.708 | 126.184 | 30.754 |
| Cash | 0.918 | ||||
| Total Receivables, Net | 1.152 | 0.747 | 0.917 | 1.998 | 2.859 |
| Prepaid Expenses | 5.522 | 5.344 | 3.418 | 1.096 | 1.007 |
| Other Current Assets, Total | 0.285 | 0 | 0.264 | 0.46 | |
| Total Assets | 155.586 | 117.176 | 122.871 | 160.698 | 36.004 |
| Property/Plant/Equipment, Total - Net | 8.333 | 10.224 | 9.197 | 2.362 | 0.285 |
| Property/Plant/Equipment, Total - Gross | 9.561 | 10.948 | 9.471 | 2.626 | 2.556 |
| Accumulated Depreciation, Total | -1.228 | -0.724 | -0.274 | -0.264 | -2.271 |
| Other Long Term Assets, Total | 1.225 | 1.723 | 3.258 | 1.949 | 0.639 |
| Total Current Liabilities | 22.324 | 14.023 | 11.948 | 9.447 | 5.398 |
| Accounts Payable | 7.777 | 4.283 | 3.144 | 2.088 | 0.545 |
| Accrued Expenses | 13.232 | 8.945 | 8.804 | 7.359 | 4.116 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.315 | 0.795 | 0 | 0 | |
| Other Current Liabilities, Total | 0.737 | ||||
| Total Liabilities | 81.535 | 52.764 | 50.072 | 31.478 | 14.404 |
| Total Long Term Debt | 32.304 | 33.139 | 33.178 | 20.097 | 7.894 |
| Long Term Debt | 32.304 | 33.139 | 33.178 | 20.097 | 7.894 |
| Other Liabilities, Total | 26.907 | 5.602 | 4.946 | 1.934 | 1.112 |
| Total Equity | 74.051 | 64.412 | 72.799 | 129.22 | 21.6 |
| Redeemable Preferred Stock | 0 | ||||
| Common Stock | 0.122 | 0.028 | 0.016 | 0.016 | 0.015 |
| Additional Paid-In Capital | 450.786 | 347.374 | 267.077 | 261.367 | 156.63 |
| Retained Earnings (Accumulated Deficit) | -376.738 | -282.871 | -194.175 | -132.044 | -135.286 |
| Other Equity, Total | -0.119 | -0.119 | -0.119 | -0.119 | 0.241 |
| Total Liabilities & Shareholders’ Equity | 155.586 | 117.176 | 122.871 | 160.698 | 36.004 |
| Total Common Shares Outstanding | 121.667 | 28.1277 | 16.3057 | 16.1289 | 2.42871 |
| Cash & Equivalents | 121.718 | 81.787 | 78.708 | 126.184 | 29.836 |
| Goodwill, Net | 17.351 | 17.351 | 27.109 | 27.109 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 98.222 | 128.677 | 85.718 | 52.585 | 70.881 |
| Cash and Short Term Investments | 93.406 | 121.718 | 79.855 | 47.378 | 66.427 |
| Cash & Equivalents | 93.406 | 121.718 | 79.855 | 47.378 | 66.427 |
| Total Receivables, Net | 0.658 | 1.152 | 0.909 | 0.843 | 0.868 |
| Prepaid Expenses | 3.908 | 5.807 | 4.954 | 4.364 | 3.586 |
| Total Assets | 124.405 | 155.586 | 113.406 | 81.019 | 99.625 |
| Property/Plant/Equipment, Total - Net | 7.83 | 8.333 | 8.8 | 9.285 | 9.747 |
| Property/Plant/Equipment, Total - Gross | 9.185 | 9.561 | 9.904 | 10.265 | 10.604 |
| Accumulated Depreciation, Total | -1.355 | -1.228 | -1.104 | -0.98 | -0.857 |
| Goodwill, Net | 17.351 | 17.351 | 17.351 | 17.351 | 17.351 |
| Other Long Term Assets, Total | 1.002 | 1.225 | 1.537 | 1.798 | 1.646 |
| Total Current Liabilities | 19.483 | 22.324 | 28.713 | 22.002 | 14.97 |
| Accounts Payable | 5.992 | 7.777 | 3.8 | 3.677 | 3.569 |
| Accrued Expenses | 12.937 | 13.232 | 10.292 | 9.718 | 7.986 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 72.729 | 81.535 | 51.557 | 50.946 | 49.911 |
| Total Long Term Debt | 31.827 | 32.304 | 18.733 | 24.49 | 29.809 |
| Long Term Debt | 31.827 | 32.304 | 18.733 | 24.49 | 29.809 |
| Other Liabilities, Total | 21.419 | 26.907 | 4.111 | 4.454 | 5.132 |
| Total Equity | 51.676 | 74.051 | 61.849 | 30.073 | 49.714 |
| Common Stock | 0.122 | 0.122 | 0.069 | 0.031 | 0.031 |
| Additional Paid-In Capital | 452.431 | 450.786 | 409.533 | 356.209 | 354.638 |
| Retained Earnings (Accumulated Deficit) | -400.758 | -376.738 | -347.634 | -326.048 | -304.836 |
| Other Equity, Total | -0.119 | -0.119 | -0.119 | -0.119 | -0.119 |
| Total Liabilities & Shareholders’ Equity | 124.405 | 155.586 | 113.406 | 81.019 | 99.625 |
| Total Common Shares Outstanding | 122.207 | 121.667 | 68.7346 | 30.9912 | 30.8095 |
| Current Port. of LT Debt/Capital Leases | 0.554 | 1.315 | 14.621 | 8.607 | 3.415 |
| Other Current Assets, Total | 0.25 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -93.867 | -88.696 | -62.131 | -52.807 | -43.021 |
| Cash From Operating Activities | -77.102 | -70.905 | -58.818 | -48.055 | -40.903 |
| Cash From Operating Activities | 0.513 | 0.499 | 0.351 | 0.103 | 0.155 |
| Non-Cash Items | 10.516 | 18.79 | 7.025 | 7.885 | 6.424 |
| Changes in Working Capital | 5.736 | -1.498 | -4.063 | -3.236 | -4.461 |
| Cash From Investing Activities | -0.103 | -0.615 | -1.362 | 27.232 | -0.034 |
| Capital Expenditures | -0.103 | -0.615 | -1.362 | -0.174 | -0.034 |
| Cash From Financing Activities | 117.23 | 74.245 | 12.394 | 140.661 | -4.531 |
| Financing Cash Flow Items | -4.814 | 0 | -0.278 | -0.043 | |
| Issuance (Retirement) of Stock, Net | 122.839 | 74.245 | 0.284 | 140.18 | 0.179 |
| Issuance (Retirement) of Debt, Net | -0.795 | 0 | 12.388 | 0.481 | -4.667 |
| Foreign Exchange Effects | -0.105 | -0.319 | 0.402 | -0.25 | -0.286 |
| Net Change in Cash | 39.92 | 2.406 | -47.384 | 119.588 | -45.754 |
| Cash Interest Paid | 3.006 | 2.906 | 2.099 | 1.284 | |
| Other Investing Cash Flow Items, Total | 0 | 0 | 27.406 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -24.02 | -93.867 | -64.763 | -43.177 | -21.965 |
| Cash From Operating Activities | -26.512 | -77.102 | -58.009 | -38.703 | -20.229 |
| Cash From Operating Activities | 0.127 | 0.513 | 0.389 | 0.265 | 0.133 |
| Non-Cash Items | -3.235 | 10.516 | 6.104 | 3.818 | 1.903 |
| Changes in Working Capital | 0.616 | 5.736 | 0.261 | 0.391 | -0.3 |
| Cash From Investing Activities | -0.009 | -0.103 | -0.069 | -0.06 | -0.022 |
| Capital Expenditures | -0.009 | -0.103 | -0.069 | -0.06 | -0.022 |
| Cash From Financing Activities | -2.124 | 117.23 | 56.586 | 4.609 | 4.956 |
| Issuance (Retirement) of Stock, Net | -0.443 | 122.839 | 60.693 | 5.855 | 5.877 |
| Issuance (Retirement) of Debt, Net | -1.681 | -0.795 | -0.795 | -1.234 | -0.909 |
| Foreign Exchange Effects | 0.05 | -0.105 | -0.468 | -0.271 | -0.069 |
| Net Change in Cash | -28.595 | 39.92 | -1.96 | -34.425 | -15.364 |
| Financing Cash Flow Items | 0 | -4.814 | -3.312 | -0.012 | -0.012 |
| Cash Interest Paid | 3.006 | ||||
| Other Investing Cash Flow Items, Total |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
X4 Pharmaceuticals, Inc. Company profile
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, X4 Pharmaceuticals Inc revenues decreased from $3M to $0K. Net loss applicable to common stockholders increased 65% to $102.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 21% to $47.9M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
61 North Beacon Street
4th Floor
BOSTON
MASSACHUSETTS 02134
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com